Search clinical trials for: KPI-121 Ophthalmic Suspension

Total 198 results

Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (Kauai)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (STRIDE 2)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (STRIDE 1)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (Molokini)

Diabetic Macular Edema | Retinal Vein Occlusion

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Post Surgical Ocular Inflammation and Pain

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (Maui)

Blepharitis

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Bausch & Lomb Incorporated

Completed

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Dry Eye Syndrome

United States
Actavis Inc.

Completed

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Glaucoma

United States
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Alcon Research

Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Guangzhou HuiBoRui Biological Pharmaceutical Technology...
Parexel

Unknown

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

Corneal Neovascularization

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Myopia

Singapore
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Padagis LLC

Completed

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Glaucoma, Open-Angle

United States
Parion Sciences

Terminated

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Alcon Research

Terminated

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Ocular Hypertension | Open-Angle Glaucoma
PanOptica, Inc.

Completed

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, United Kingdom, Hungary, Latvia
Qlaris Bio, Inc.

Completed

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Ocular Hypertension | Glaucoma | Sturge-Weber Syndrome

United States
Alcon Research

Completed

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Confirmatory Study Nepafenac 0.3%

Cataract

United States
Qlaris Bio, Inc.

Recruiting

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Glaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)

United States
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Leber's Hereditary Optic Neuropathy

United States
Betaliq, Inc.
Trial Runners, LLC; Summit Analytical, LLC

Completed

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Qlaris Bio, Inc.

Recruiting

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Primary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma or Ocular Hypertension

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Alcon Research

Completed

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

Age-Related Macular Degeneration
Price Vision Group
Kala Pharmaceuticals, Inc.

Completed

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Corneal Edema | Corneal Endothelial Dystrophy

United States
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Actavis Inc.

Completed

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

Healthy

Canada
Instituto de Oftalmología Fundación Conde de Valenciana

Completed

Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

Cataract Senile | Microbial Disease

Mexico
Actavis Inc.

Completed

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

Healthy

Canada
Alcon Research

Completed

Tobramycin Tear Concentrations

Dry Eye

United States
Alcon Research

Completed

Nepafenac 0.3% Two Study

Cataract

United States
Alcon Research

Terminated

Macular Edema Incidence/Severity Reduction With Nevanac

Diabetic Retinopathy

United States
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

3

Subscribe